ATTENTION: Income Investors

DIVIDEND ACCELERATORS WEEKLY:

URGENT: 4 Quality Dividend Stocks With Ex-Dates Before January 20th

Progressing...
Editor's Note:
In light of recent market volatility and increasing interest in defensive stocks, we've compiled detailed analyses of key dividend aristocrats and stable growth companies - all demonstrating resilient business models and consistent dividend growth.

If you're interested in dividend investing strategies, I strongly recommend watching "Follow Warren Buffett's move, but with 21X more dividends" from one of our trusted partners.
Stock Profile - Quest Diagnostics (DGX)

Quest Diagnostics

NYSE: DGX
$134.87
+$0.95 (0.71%) Volume: 892,345

Why We're Watching

Quest Diagnostics stands as a leading provider of diagnostic testing services in the United States, with a robust network of laboratories and patient service centers. The company's strategic initiatives in advanced diagnostics, consumer-directed testing, and healthcare technology position it well in the evolving healthcare landscape.

Market Cap
$15.2B
P/E Ratio
19.4x
Dividend Yield
2.12%
Beta
0.92

Key Dates

Earnings Date
Feb 1, 2024
Ex-Dividend Date
Jan 17, 2024
Dividend Payment
Jan 31, 2024

Analyst Coverage

6
Buy
8
Hold
1
Sell
$142
Avg Target
15
Total Ratings
Consensus: Hold

Strengths

  • Market leadership in diagnostics
  • Extensive testing network
  • Strong healthcare relationships
  • Advanced testing capabilities
  • Robust cash flow generation

Risks

  • Reimbursement pressure
  • Competitive market
  • Healthcare regulation changes
  • Volume fluctuations
  • Labor cost pressures

Final Thoughts

Quest Diagnostics maintains a strong position in the diagnostic testing market with its extensive network and comprehensive test menu. While facing post-COVID normalization in testing volumes, the company's focus on operational efficiency, advanced diagnostics, and consumer-initiated testing presents growth opportunities. Quest's solid balance sheet, consistent dividend payments, and strategic initiatives in healthcare technology and precision medicine support long-term value creation. The company's scale advantages and ongoing investments in automation and digital capabilities should help maintain its competitive edge in the evolving healthcare diagnostics landscape.

Before You Unlock The Next Stock Profile...

Member Access Component

This Is By Far My #1 Income Stock

I am often asked what my favorite dividend stock is.
$19.9B
Revenue Last Year
$5.6B
Paid in Dividends
$35B
Expected Future Sales
This Is By Far My #1 Income Stock
I am often asked what my favorite dividend stock is.  
So I want to share the one single stock that's by far my favorite right now.
Unlike many dividend-paying companies... which rely on boring income through utilities, rent or oil...
This company owns the bestselling drug in the world, which brought in $19.9 billion in revenue last year.
And it has a pipeline of other blockbuster drugs, which are expected to generate $35 billion in sales.
It doesn't take a genius to know that healthcare is at the forefront of everyone's mind right now, including the folks on Wall Street.
Last year, this company's stellar drug sales allowed it to pay shareholders $5.6 billion in dividends.
That's cash you can claim a piece of.
And today, I want to give you the name, the ticker symbol and my full analysis completely free - no strings attached. 
YES, I WANT TO WATCH THIS NOW >>
Sincerely,
Marc Lichtenfeld
Chief Income Strategist, The Oxford Club
P.S. When I say FREE, I mean it. There is no catch. You get my entire Ultimate Dividend Package... including my No. 1 dividend stock... free of charge. Here's how.

looking for opportunities?

YOU NEED TO CLICK BELOW...

Dividend Expert Reveals His Biggest Income Secrets... Free of Charge

Marc Lichtenfeld –Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package...

Free of charge!

Ultimate Dividend Package

Click Here to Get His #1 Dividend Stock... The Safest 9% Dividend in the World... Top Three "Extreme Dividend" Stocks, And Much, Much More.

YES, I WANT TO WATCH THIS NOW >>

Disclaimer

DividendWealthBuilders.com, a brand under Market Insiders Media dba, operates under the parent company Sandpiper Marketing Group, LLC. Please be advised that DividendWealthBuilders.com is not registered as an investment adviser or broker-dealer with the United States Securities and Exchange Commission or any state regulatory agency. We rely on the "publisher's exclusion" from the definition of investment adviser as set forth in Section 202(a)(11) of the Investment Advisers Act of 1940, as amended, as well as corresponding state securities laws. Consequently, DividendWealthBuilders.com does not offer or provide personalized investment advice.

The information we provide is based on our opinions, statistical and financial data, and independent research of public information. Our materials are intended for informational purposes only, and no mention of a specific security in any of our content constitutes a recommendation to buy, sell, or hold that or any other security. Any information deemed to be investment opinion is impersonal and not tailored to the investment needs of any individual.

Please be aware that DividendWealthBuilders.com does not promise, guarantee, or imply that any information provided through our websites, newsletters, reports, or printed material will result in profit or loss. We strongly encourage you to seek personal advice from your professional investment, tax, or legal advisors and to conduct your own due diligence and independent investigations before acting on any information we publish or making any investment decision. Only you and your professional advisors can determine the level of risk appropriate for you. Penny stocks, in particular, are inherently speculative investments, and you should be prepared to lose your entire investment.

Employees, owners, and/or writers of DividendWealthBuilders.com may own positions in the equities, options, and/or securities mentioned in our content. However, no associated employees will intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. DividendWealthBuilders.com may be compensated for publishing information about companies referred to in our reports, newsletters, and websites, and we provide full disclosure of such compensation.

Furthermore, please note that any content marked as "Sponsor" may be paid for and is not endorsed or warranted by our staff or company. The content in our emails is for educational or entertainment use and is not a substitute for professional advice or an offer to buy or sell any securities. Neither the publisher nor the editors are registered investment advisors (RIA’s) and do not provide personalized counseling. Be sure to conduct your own careful research and consult with your advisors before taking any action based on our content. By opening our emails or clicking any links contained therein, you are reconfirming your opt-in status, which is part of your free subscription.